The primary objective of this clinical study is to evaluate the effectiveness and safety of
PH3 for patients with diabetic nephropathy.
The secondary objectives are to identify the optimal dosage for subsequent studies and to
provide basis for the next confirmatory study in study design, endpoints, and study
methodologies.